The Global Non-Small Cell Lung Carcinoma (NSCLC) Market is on the brink of an extraordinary transformation, with market ...

SALES FORECAST: The Swiss pharma giant's third-quarter sales are forecast at 14.89 billion Swiss francs ($17.22 billion), according to a consensus of 11 analysts' estimates compiled by Visible Alpha.

Here's a recap of the week’s most important stories.

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG (RHHVF – Research ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into earl ...

Roche's stock demonstrated resilience on the Swiss Stock Exchange SIX, fluctuating between 268.70 CHF and 272.20 CHF with a trading volume exceeding 247,000 shares. Despite a slight dip of 0.61% on Oc ...

Next-Generation Digital Cockpit Market is set to grow from USD 25.6 Bn in 2023 to USD 61.4 Bn by 2032, with a CAGR of 10.5% ...

Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

Cathie Wood, the CEO of Ark Invest, has several AI stocks in her investment management firm's actively managed ETFs. One of ...